Skip to main content

Table 2 Treatment-emergent adverse events (TEAE) occurring in at least 5% of patients who received duloxetine

From: Safety and efficacy of duloxetine treatment in older and younger patients with osteoarthritis knee pain: a post hoc, subgroup analysis of two randomized, placebo-controlled trials

  Older Younger  
  Placebo N=94 n (%) Duloxetine N=103 n (%) Placebo N=154 n (%) Duloxetine N=136 n (%) Treatment-by-Age Group Interaction p values
Patients with at least one TEAE 40(42.6) 55(53.4) 51 (33.1) 65(47.8) .66a
Constipation 2 (2.1) 11 (10.7) 0 (0) 3 (2.2) 1.00b
Diarrhea 2 (2.1) 4 (3.9) 4 (2.6) 7 (5.1) .93
Dizziness 3 (3.2) 1 (1.0) 1 (0.6) 9 (6.6) .02
Nausea 3 (3.2) 9 (8.7) 2 (1.3) 11 (8.1) .40c
Somnolence 3 (3.2) 6 (5.8) 1 (0.6) 4 (2.9) .49
Patients with at least one SAE 2 (2.1) 3 (2.9) 2 (1.3) 1 (0.7) .57
  1. a treatment effect, p=.005.
  2. b treatment effect, p=.03.
  3. c treatment effect, p=.004.
  4. Abbreviations: TEAE, treatment-emergent adverse event; SAE, serious adverse event.